A Phase 2/3, Open-label, Single-Arm Study in the Pediatric Population With HIV-1 to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Long-Acting Regimen of Lenacapavir, Teropavimab, and Zinlirvimab Administered Twice Yearly | Arctuva